Search results for "AGENTS"

showing 10 items of 7330 documents

The effect of ezetimibe on NAFLD

2015

NAFLD has become the most common liver disorder in countries, where obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome are common. The strong association between these conditions and the risk of cardiovascular disease make treatment crucial. Possible interventions for NAFLD target excess body weight, insulin resistance, inflammation, oxidative stress or intestinal lipid absorption. Administration of combination therapy with a statin plus ezetimibe, associated with lifestyle changes, may represent an effective strategy because of the strong reduction in low-density lipoprotein cholesterol levels. Combination therapy is often more effective, especially when complementary …

medicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classBioinformaticsLiver disorderInsulin resistanceEzetimibeInternal medicineInternal MedicineAnimalsHumansMedicinebusiness.industryAnticholesteremic AgentsIntestinal lipid absorptionnutritional and metabolic diseasesGeneral MedicineLipid Metabolismmedicine.diseaseEzetimibeTreatment OutcomeEndocrinologyCholesterolLiverAzetidinesDrug Therapy CombinationMetabolic syndromebusinessCardiology and Cardiovascular MedicineNon-alcoholic steatohepatitiDyslipidemiamedicine.drugNon-alcoholic fatty liver disease
researchProduct

P705Step by step diagnosis and management of statin intolerance: position paper from an international lipid expert panel

2019

Abstract Background Statin intolerance is a clinical syndrome whereby adverse effects associated with statin therapy (most commonly muscle symptoms) result in the discontinuation of therapy. Statin discontinuation is associated with increased risk of adverse cardiac outcomes. Many patients who initially experience adverse effects are able to tolerate statin therapy to some extent. Careful stepwise diagnosis and management of individuals who experience adverse effects is essential to enable optimal reduction of cardiovascular risk. Purpose In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step by step approach to the diagnosis and practical management of sta…

medicine.medical_specialtyStatinbusiness.industrymedicine.drug_classExpert opinionMedicineANTILIPEMIC AGENTSPosition paperCardiology and Cardiovascular MedicinebusinessIntensive care medicineLipid-lowering therapyEuropean Heart Journal
researchProduct

Rational for statin use in psoriatic patients

2013

Psoriasis represents a common skin disease which is clinically manifested by chronic cutaneous lesions. It has been observed that psoriasis is associated with an increased risk of cardiovascular diseases, which is contributed to the inappropriate lipid metabolism. Statins are commonly used in clinical practice to lower cholesterol concentration and, accordingly, decrease the individual risk of developing a cardiovascular episode. There have been reports that statin administration could also result in better management of psoriasis. The observed beneficial effects are contributed to the effects on lipid metabolism, including that in skin, as well as anti-inflammatory and immunomodulatory pro…

medicine.medical_specialtyStatinmedicine.drug_classAtorvastatinDermatologyDiseasePharmacologychemistry.chemical_compoundPsoriasisInternal medicinemedicineAnimalsHumansPsoriasiscardiovascular diseasesSkinCholesterolbusiness.industrynutritional and metabolic diseasesPsoriasis Statins Cholesterol Atorvastatin Fluvastatin SimvastatinGeneral Medicinemedicine.diseaseTreatment OutcomechemistrySimvastatinlipids (amino acids peptides and proteins)Dermatologic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPravastatinmedicine.drugFluvastatin
researchProduct

GLP-1 receptor agonists in NAFLD.

2017

IF 4.101; International audience; Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed.

medicine.medical_specialtySteatosisEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiseaseType 2 diabetesGastroenterologyGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyFibrosisWeight lossInternal medicineInternal MedicineHumansHypoglycemic AgentsMedicineReceptorGlucagon-like peptide 1 receptorGLP-1 receptor agonistsbusiness.industryFatty livernutritional and metabolic diseasesGeneral Medicine[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseaseFibrosisdigestive system diseasesTreatment OutcomeDiabetes Mellitus Type 2030211 gastroenterology & hepatologytype 2 diabetesSteatosismedicine.symptombusinessNon-alcoholic fatty liver disease
researchProduct

Pharmacotherapy of female urinary incontinence

2005

Urinary incontinence is a major clinical problem and a significant cause of disability and dependency in older adults. Overall, the prevalence of urinary incontinence approaches 55% among women aged over 55 years. The past few years have seen significant advances in the pharmacotherapy of overactive bladder and stress incontinence. The review examines the evidence regarding their benefits and side-effects.

medicine.medical_specialtyStress incontinencebusiness.industryHealth StatusUrinary Incontinence StressAnti-Infective Agents UrinaryUrologyObstetrics and GynecologyEstrogensUrinary incontinenceMuscarinic AntagonistsMiddle Agedmedicine.diseaseAdrenergic AgonistsCholinergic AntagonistsPharmacotherapyOveractive bladderInternal medicineQuality of LifeHumansWomen's HealthMedicineFemalemedicine.symptombusinessBritish Menopause Society Journal
researchProduct

Erythropoietin and the heart: physiological effects and the therapeutic perspective.

2014

Erythropoietin (Epo) has been thought to act exclusively on erythroid progenitor cells. The identification of Epo receptor (EpoR) in non-haematopoietic cells and tissues including neurons, astrocytes, microglia, immune cells, cancer cell lines, endothelial cells, bone marrow stromal cells, as well as cells of myocardium, reproductive system, gastrointestinal tract, kidney, pancreas and skeletal muscle indicates that Epo has pleiotropic actions. Epo shows signals through protein kinases, anti-apoptotic proteins and transcription factors. In light of interest of administering recombinant human erythropoietin (rhEpo) and its analogues for limiting infarct size and left ventricular (LV) remodel…

medicine.medical_specialtyStromal cellCardiotonic AgentsAngiogenesisNeovascularization PhysiologicInflammationerythroid progenitor cellshemic and lymphatic diseasesInternal medicineEpo receptorReceptors ErythropoietinMedicineHumansErythropoietinCardioprotectionMicrogliabusiness.industryHeartErythropoietin receptorErythropoietin; Epo receptor; erythroid progenitor cellsEndocrinologymedicine.anatomical_structureErythropoietinCancer researchAirway RemodelingBone marrowmedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugInternational journal of cardiology
researchProduct

Erythropoietin for Subarachnoid Hemorrhage: Is There a Reason for Hope?

2011

I b S a r a S ubarachnoid hemorrhage (SAH) associated with a ruptured cerebral aneurysm remains a source of significant morbidity and mortality, not only from the initial hemorrhage but lso from the delayed complications, such as cerebral vasospasm ften severe enough to induce irreversible changes in cerebral erfusion. Several drugs have been developed that have the otential to limit cerebral vasospasm and delayed ischemic eurologic deficit, thus improving outcome for patients. Howver, although numerous agents that can prevent arterial narrowng and/or block the excitatory cascade of events leading to schemic neuronal death in experimental conditions, there is still o pharmacologic agent tha…

medicine.medical_specialtySubarachnoid hemorrhageErythropoietin subarachnoid hemorrhageBlood volumeAneurysm RupturedNeuroprotectionAneurysmCerebral vasospasmInternal medicinemedicineErythropoietin; Neuroprotection; Subarachnoid hemorrhageHumansSubarachnoid hemorrhageErythropoietinSettore MED/27 - Neurochirurgiabusiness.industryEpoetin alfaPharmacologic Agentmedicine.diseaseRecombinant ProteinsNeuroprotectionEpoetin AlfaNeuroprotective AgentsErythropoietinCardiologySurgeryNeurology (clinical)businessmedicine.drug
researchProduct

Cognitive effects of labeled addictolytic medications

2017

Abstract Introduction Alcohol, tobacco, and illegal drug usage is pervasive throughout the world, and abuse of these substances is a major contributor to the global disease burden. Many pharmacotherapies have been developed over the last 50 years to target addictive disorders. While the efficacy of these pharmacotherapies is largely recognized, their cognitive impact is less known. However, all substance abuse disorders are known to promote cognitive disorders like executive dysfunction and memory impairment. These impairments are critical for the maintenance of addictive behaviors and impede cognitive behavioral therapies that are regularly administered in association with pharmacotherapie…

medicine.medical_specialtySubstance-Related Disordersmedia_common.quotation_subjectAlcohol abuse03 medical and health scienceschemistry.chemical_compoundCognition0302 clinical medicinemedicineAnimalsHumansVareniclinePsychiatryBiological PsychiatryNalmefenemedia_commonPharmacologyAddictionCognitionmedicine.disease030227 psychiatrySubstance abusechemistryPsychology030217 neurology & neurosurgeryCentral Nervous System AgentsClinical psychologymedicine.drugExecutive dysfunctionBuprenorphineProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct

Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature …

2010

Summary Background There is clear evidence from two systematic reviews that radiotherapy (RT) reduces the risk of local recurrence in patients with resectable rectal cancer, though the data on survival are still equivocal. Objective To assess the effects of chemotherapy combined concomitantly with radiotherapy (CRT) on the increase of overall survival, and on the prevention of local recurrence and distant metastases. Data sources Computerized bibliographic searches of MEDLINE and CANCERLIT (1970–2008) were supplemented with hand searches of reference lists. Study selection Studies were included if they were randomized controlled trials (RCTs) comparing preoperative or postoperative CRT to p…

medicine.medical_specialtySurvivalColorectal cancermedicine.medical_treatmentPopulationAntineoplastic Agentslaw.inventionRectal carcinomaRandomized controlled triallawRisk of mortalityHumansMedicineMeta-analysiRadiology Nuclear Medicine and imagingNeoplasm Metastasiseducationeducation.field_of_studyRadiotherapyRectal Neoplasmsbusiness.industryChemoradiotherapyGeneral Medicinemedicine.diseaseCombined Modality TherapySurgeryRadiation therapyOncologyConcomitantMeta-analysisbusinessPublication BiasChemoradiotherapyCancer Treatment Reviews
researchProduct

Is global elimination of HCV realistic?

2017

The elimination of hepatitis C virus (HCV) has been made possible through the availability of new antiviral drugs which may now be administered to all patients with HCV infection, even those with decompensated cirrhosis. The goal of the World Health Organization (WHO) is to reduce the incidence of chronic hepatitis infection from the current 6-10 million to 0.9 million cases of chronic infections by 2030, and annual deaths from 1.4 million to fewer than 0.5 million. Achieving these targets will require full implementation of epidemiological knowledge of HCV infection, screening and testing practices and strategies to link HCV patients to care. This review will focus on the current state of …

medicine.medical_specialtySustained Virologic ResponseHepatitis C virusCost-Benefit Analysismedicine.disease_causeGlobal HealthWorld Health OrganizationAntiviral AgentsWorld health03 medical and health sciences0302 clinical medicineChronic hepatitisInternal medicineEpidemiologymedicineHumansMass Screening030212 general & internal medicineDisease EradicationIntensive care medicineSubstance Abuse Intravenouslinkage to caredirect antiviral agentHepatologybusiness.industryscreeningIncidence (epidemiology)Hcv clearancevirus diseasesHepatologyPatient Acceptance of Health CareHepatitis Cdigestive system diseases030211 gastroenterology & hepatologybusinessPatient awarenessLiver international : official journal of the International Association for the Study of the Liver
researchProduct